XML 19 R4.htm IDEA: XBRL DOCUMENT v3.25.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Total revenues $ 6,667 $ 6,686
Costs and expenses:    
Cost of goods sold 1,540 1,552
Research and development expenses 1,379 1,520
Acquired in-process research and development expenses 253 4,131
In-process research and development impairments 0 2,430
Selling, general and administrative expenses 1,258 1,375
Total costs and expenses 4,430 11,008
Operating income (loss) 2,237 (4,322)
Interest expense 260 254
Other (income) expense, net 328 (91)
Income (loss) before income taxes 1,649 (4,486)
Income tax expense (benefit) 334 (315)
Net income (loss) 1,315 (4,170)
Net income attributable to noncontrolling interest 0 0
Net income (loss) attributable to Gilead $ 1,315 $ (4,170)
Basic earnings (loss) per share attributable to Gilead (in dollars per share) $ 1.06 $ (3.34)
Diluted earnings (loss) per share attributable to Gilead (in dollars per share) $ 1.04 $ (3.34)
Shares used in basic earnings (loss) per share attributable to Gilead calculation (in shares) 1,246 1,247
Shares used in diluted earnings (loss) per share attributable to Gilead calculation (in shares) 1,259 1,247
Product sales    
Revenues:    
Total revenues $ 6,613 $ 6,647
Royalty, contract and other revenues    
Revenues:    
Total revenues $ 54 $ 39